首页 > 市场调查报告书 > 製药

妇科治疗

市场调查报告书

商品编码

1482456

全球性交困难治疗市场：依药物类型、给药途径、通路及地区划分

Dyspareunia Treatment Market, By Drug Type (Selective Estrogen Receptor Modulators, Estrogens, Corticosteroids, Antibiotics, and Others), By Route of Administration, By Distribution Channel, By Geography

出版日期: 2024年04月10日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年全球性交困难治疗市场规模将达7.541亿美元，2024年至2031年复合年增长率为4.6%，2031年将达到10.354亿美元。

报告范围		报告详情
基准年	2023年	2024年市场规模	7.541 亿美元
实际资料	2019-2023	预测期	2024-2031
预测期，2024-2031年复合年增长率：	4.60%	2031 年金额预测	10.354 亿美元

图：2024 年按地区分類的性交困难治疗市场占有率(%)

性交困难（性交困难）是全世界女性常见的问题。其特征是插入期间或插入后骨盆区域内或周围疼痛，并对身体和心理产生影响。确切原因因人而异，但常见原因包括阴道感染疾病、子宫内膜异位症、心理因素、分娩时骨盆区域受伤。如果不及时治疗，可能会对生活品质和性关係产生负面影响。性功能障碍治疗市场包括一系列缓解疼痛和恢復亲密关係的药物和医疗设备。荷尔蒙疗法、物理治疗和微创手术等治疗领域的进步扩大了有效治疗这种疾病的选择。

市场动态：

人们对现有治疗方案的认识不断提高，对女性性行为的讨论也更加公开，正在推动性交困难治疗市场的发展。随着患者感觉更有权力寻求治疗，围绕女性健康问题的历史耻辱正在逐渐减少。对药理管理的非侵入性和非药物替代品的需求不断增长，正在扩大该领域物理治疗工具和医疗设备的机会。然而，新技术的高成本可能会在一定程度上限制市场扩张。文化和社会障碍继续阻碍一些地区的寻求帮助。同时，患有骨盆底疾病和神经系统问题的人口老化为市场参与企业带来了新的前景。

本研究的主要特点

该报告详细分析了全球性交困难治疗市场，包括以2023年为基准年的预测期（2024-2031年）的市场规模（百万美元）和年复合成长率（CAGR%）。
它还强调了各个细分市场的潜在收益成长机会，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球性功能障碍治疗市场的主要企业。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
全球性交困难治疗市场迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过用于分析全球性交困难治疗市场的各种策略矩阵来促进他们的决策。

公司简介
- Lupin
- Pfizer Inc.
- AbbVie Inc.
- Duchesnay Inc.
- AMAG Pharmaceuticals, Inc.
- Amneal Pharmaceuticals LLC.
- TherapeuticsMD, Inc.
- Sumitomo Pharma Co., Ltd.,
- Myovant Sciences
- Novo Nordisk A/S
- Viatris Inc.
- Shionogi & Co., Ltd.
- Millicent Pharma Ltd.
- Cosette Pharmaceuticals, Inc.
- Mundipharma International

第10章分析师的观点

第十一章参考文献与调查方法

简介目录

Product Code: CMI6885

The dyspareunia treatment market is estimated to be valued at USD 754.1 Mn in 2024 and is expected to reach USD 1,035.4 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 754.1 Mn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	4.60%	2031 Value Projection:	US$ 1,035.4 Mn

Figure. Dyspareunia Treatment Market Share (%), By Region 2024

Dyspareunia, or painful sexual intercourse, is a prevalent issue that affects women globally. It is characterized by pain in the pelvic region or surrounding area during or after penetration, and has physical as well as psychological implications. The exact causes may vary from person to person, but common contributors include vaginal infections, endometriosis, psychological factors, and pelvic area injuries during childbirth. If left untreated, it can have a negative impact on quality of life and sexual relationships. The dyspareunia treatment market consists of pharmaceutical and medical device options that provide relief from pain and help restore intimacy. Advancements in therapeutic areas like hormonal therapy, physical therapy, and minimally invasive procedures are expanding choices for managing this condition effectively.

Market Dynamics:

Rising awareness about available treatment choices and more open discussion of female sexuality are driving the dyspareunia treatment market. Historical stigma around women's health issues is gradually reducing as patients feel more empowered to seek care. Growing demand for non-invasive and non-drug alternatives to pharmacological management is opening up opportunities for physical therapy tools and medical devices in this space. However, high costs associated with newer technologies could restrict market expansion to some degree. Cultural and social barriers continue to hamper help-seeking behavior in certain regions as well. Meanwhile, an aging population presenting with pelvic floor disorders and neurological issues presents new prospects for market participants.

Key Features of the Study:

This report provides an in-depth analysis of the global dyspareunia treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dyspareunia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes Lupin, Pfizer Inc., AbbVie Inc., Duchesnay Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., TherapeuticsMD, Inc., Sumitomo Pharma Co., Ltd., Myovant Sciences, Novo Nordisk A/S, Viatris Inc., Shionogi & Co., Ltd., Millicent Pharma Ltd., Cosette Pharmaceuticals, Inc., and Mundipharma International
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dyspareunia treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dyspareunia treatment market

Detailed Segmentation-

Drug Type:
- Selective Estrogen Receptor Modulators
- Estrogens (Miscellaneous Vaginal Agents)
- Corticosteroids
- Antibiotics
- Others
Route of Administration:
- Oral
- Vaginal Inserts
- Others
Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- E-Commerce
- Others
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Lupin
- Pfizer Inc.
- AbbVie Inc.
- Duchesnay Inc.
- AMAG Pharmaceuticals, Inc.
- Amneal Pharmaceuticals LLC.
- TherapeuticsMD, Inc.
- Sumitomo Pharma Co., Ltd.,
- Myovant Sciences
- Novo Nordisk A/S
- Viatris Inc.
- Shionogi & Co., Ltd.
- Millicent Pharma Ltd.
- Cosette Pharmaceuticals, Inc.
- Mundipharma International

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Product Launches/Approvals
Fundings and Investments
Reimbursement Scenario
PEST Analysis
Porter's Analysis

4. Global Dyspareunia Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Dyspareunia Treatment Market, By Drug Type, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Selective Estrogen Receptor Modulators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Estrogens (Miscellaneous Vaginal Agents)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Dyspareunia Treatment Market, By Route of Administration, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Vaginal Inserts
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Dyspareunia Treatment Market, By Distribution Channel, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
E-commerce
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Dyspareunia Treatment Market, By Region, 2019 - 2031, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - U.S.
  - Canada
  - Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
  - Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
  - Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
  - Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Lupin*
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Duchesnay Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AMAG Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amneal Pharmaceuticals LLC.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- TherapeuticsMD, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sumitomo Pharma Co., Ltd.,
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Myovant Sciences
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novo Nordisk A/S
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Viatris Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Shionogi & Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Millicent Pharma Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Cosette Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Mundipharma International
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies

10. Analyst View

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

全球性交困难治疗市场：依药物类型、给药途径、通路及地区划分